New immune booster aims to stop childhood cancer relapse after transplant
Disease control
Not yet recruiting
This early-phase trial tests a new therapy called ThINKK in 12 children aged 2–12 who had a stem cell transplant for leukemia or neuroblastoma. The therapy uses specially designed immune cells to help the body's natural killer cells fight any remaining cancer cells. The main goal…
Phase: PHASE1 • Sponsor: Michel Duval • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC